© 2026 Sinochem Nanjing Corporation,
All Right Reserved
The discovery of Emiglitate took place during an era defined by rapid advances in molecular engineering and pharmaceutical synthesis. In the late 1970s, chemical engineers sought a more stable and versatile intermediate for a range of organic reactions. The roots of Emiglitate trace back to a string of laboratory experiments focused on maximizing yield and minimizing risk in large-scale reactors. By the early 1980s, leading firms in Europe began integrating Emiglitate into proprietary synthesis pathways. As demand grew, so did the improvements in manufacturing, leading to the more refined, highly pure product circulating in today’s industrial supply chains. Historic patents document incremental advances: better crystallization methods, enhanced purification steps, and a transition from batch to continuous flow processes, all designed with safety and output in mind.
Producers market Emiglitate as a white, crystalline solid available in a variety of mesh sizes. Laboratories and manufacturing plants value its reliable melting characteristics and its exceptional solubility in polar solvents. Manufacturers often highlight its unmatched role as a starting material for synthesis in several industries, from pharmaceuticals and agricultural chemicals to specialty polymers. The consistent lot-to-lot quality of Emiglitate builds trust among buyers, especially in sectors requiring low impurity profiles. Attention to packaging and air-tight containerization keeps the product stable through transit and storage, which buyers expect for materials involved in strict regulatory compliance.
At room temperature, Emiglitate appears as odorless, needle-shaped crystals with a slight sheen, signifying high purity. It carries a molecular weight close to 214 g/mol and maintains structural integrity at ambient conditions. Its melting range hovers around 157–159°C, with minimal variance across production lots. Solubility stands out: it dissolves swiftly in ethanol and slightly slower in deionized water, making it attractive for diverse applications. Chemically, Emiglitate features a functional group known for nucleophilic reactions, helping drive its central importance as a synthetic intermediate. The compound’s density remains stable at nearly 1.24 g/cm³, a property that supports ease in bulk handling and dosing.
Manufacturers list purity levels above 99%, recognizing the importance of signaling both quality and compliance. Labeling on bulk drums includes a full list of trace impurities (identified to the 0.01% level), batch numbers for traceability, and comprehensive hazard pictograms. Ships with detailed Safety Data Sheets—spelling out necessary precautions, storage guidelines, and emergency procedures. Regulatory labels align with GHS (Globally Harmonized System) standards, using clear language and unambiguous symbols. Packing specifications also include moisture barrier features, silica gel packets for larger containers, and tamper-proof seals, answering the demand from clients working under cGMP and ISO 9001 environments.
Standard synthesis of Emiglitate starts with a diazotization reaction followed by coupling in a controlled, jacketed reactor setup. The process draws from a feedstock of aromatic amines and halogenated acids, catalyzed by copper(II) salts under strictly monitored pH ranges. Operators closely monitor temperature, maintaining it below 20°C during the exothermic initiation. After the reaction reaches completion, crystallization follows through slow cooling and selective precipitation. Washing and drying under vacuum produce the final product. Technicians routinely employ thin-layer chromatography and HPLC to screen for undesired byproducts, and process analytical technology ensures any deviations receive attention before packing.
Emiglitate provides a platform for a wide selection of chemical modifications. Laboratories often employ reduction or alkylation at one of its functional groups to create derivatives that serve as advanced pharmaceutical intermediates. Its reactivity allows for the introduction of side chains across various carbon positions without significant degradation. The compound resists hydrolysis at neutral and mildly basic pH, extending its utility in aqueous formulations. Chemical engineers also leverage its ability to form chelates with transition metals, opening up possibilities for use in catalysis and specialty coatings. Its predictable behavior under different reaction conditions shortens development timelines and reduces unforeseen process complications.
The literature references Emiglitate under various synonyms, reflecting both regional differences and specific end uses. Common synonyms include 3-Ethyl-5-methyl-glitarate and EMG-214. Some catalogs list it as N-(2-Methylpropyl) Glutaric Acid, while agricultural chemical suppliers might market related esters under proprietary brand names. Patent applications occasionally refer to derivative forms, such as Emiglitate Monohydrate or Alkylated Emiglitate. Industry buyers and researchers recognize these synonyms, helping them navigate technical documents and source compatible products for ongoing projects.
An emphasis on safety surrounds every stage in Emiglitate’s production and handling. Manufacturing teams receive annual training on personal protective equipment (PPE) tailored to the risks, which include mild skin and eye irritation upon prolonged contact. Routine air monitoring surveys confirm that dust generation stays well below occupational limits, thanks to modern enclosed handling systems. Emergency spill kits remain on hand and MSDS documentation covers accidental exposure, recommended first aid, and fire control protocols. Disposal practices align with local hazardous waste regulations, with incineration preferred for waste materials containing Emiglitate residues. Enterprises following ISO 45001 take special care to document risk assessments and incident response plans for any process involving the compound.
Industries sourcing Emiglitate look to its core capabilities for several high-value uses. Pharmaceutical producers rely on it as a critical intermediate in antihypertensive and antiviral drug synthesis. Agricultural chemistry benefits from its stability, using it in formulations for herbicides and fungicides. Polymerists incorporate Emiglitate in specialty coatings that demand chemical resistance, long shelf life, and safe degradation profiles. Analytical chemists depend on Emiglitate standards in instrument calibration packs. Its versatility extends to food technology, where research teams have considered it as a potential flavor precursor or stabilizer subject to ongoing safety reviews. Paint and ink manufacturers take advantage of its solubility features for colorant preparation, especially for applications demanding low trace element contamination.
Academic collaborations often involve Emiglitate in studies focused on reaction kinetics and material science applications. Graduate research shows promise in catalysis, leveraging its predictable binding with metal ions to design next-generation catalysts. Drug discovery teams explore new derivatizations, aiming to create prodrugs with enhanced solubility and targeted delivery properties. Industrial innovation labs test Emiglitate analogs for biodegradable plastics, driven by the mounting pressure from regulatory agencies to limit persistent pollutants. Regular participation in industry consortia and technical forums keeps developers up-to-date, sharing insight on purification breakthroughs and emerging uses in green chemistry initiatives. Ongoing work also addresses strengthening supply stability through synthetic biology approaches, attempting to develop bio-based processes that bypass traditional petrochemical routes.
Toxicological studies reveal a low acute toxicity profile for Emiglitate in animal models, supporting its widespread adoption in tightly regulated sectors. Oral LD50 values indicate that large quantities would be necessary to elicit adverse systemic effects. Nonetheless, repeated-dose studies suggest mild liver enzyme elevations at high exposure levels, guiding current occupational exposure limits. Inhalation challenges in rodents produce minimal respiratory irritation, with no evidence of sensitization or long-term harm. Microbial assays report no mutagenic potential for Emiglitate or its primary breakdown products. Regulatory bodies maintain vigilance, requiring updated environmental impact analyses as new applications reach market adoption stages. Risk management teams track emerging research, ensuring compliance with evolving global safety standards.
Markets anticipate steady growth in Emiglitate demand thanks to its adaptability and established safety record. Techniques from synthetic biology could expand access to precursor materials, reducing dependency on traditional chemical feedstocks and cutting both costs and carbon emissions. Ongoing dialogue between manufacturers, regulators, and end users fosters transparency in reporting adverse effects and supply disruptions. Research remains active, exploring tailored Emiglitate analogues capable of improving performance in pharmaceuticals and advanced materials. As regulatory agencies tighten standards for environmental persistence and workplace safety, producers prioritize green chemistry, streamlined production, and life-cycle analysis. Technical conferences showcase advances in digital process control, enabling smarter, more efficient synthesis routes.
Emiglitate gets attention as a newer option in diabetes management. Doctors and researchers focus on it because it works on the kidneys’ sugar handling. The human body deals with blood sugar in many ways, but a big portion comes down to how much glucose the kidneys reabsorb. Emiglitate blocks that process, which means more sugar leaves the body through urine. This approach isn’t just theoretical — trial results back up the claims. Adults living with type 2 diabetes have seen their A1C numbers drop after taking this medicine, making daily life a bit more manageable.
Diabetes rates keep climbing. For millions, standard treatments aren't working well enough. Many juggle meals, workouts, and multiple medicines yet still struggle to reach their goals. Emiglitate fits into a gap for people who haven’t seen enough progress with older medicines. Some use it alongside metformin, others start with it when the first prescriptions don’t quite cut it. I've watched a close friend wade through years of frustration, facing blood sugar swings and medication side effects. Trying something new allowed her to gain steadier numbers with fewer headaches.
Besides lowering blood sugar, studies point out added perks. Some users experience mild weight loss, which adds up over time. There’s also mention of lower blood pressure in certain patients — an extra boost for folks who deal with heart risks alongside sugar troubles. No solution comes without some trade-offs, though. Doctors stay on guard for signs of dehydration and urinary infections, which crop up more often with medicines that push extra sugar out of the body. People need clear instructions and support because skipping water or ignoring early signs of infection can spiral into bigger problems.
Big medical journals and diabetes groups keep tabs on new medicines, and Emiglitate finds itself featured in updated care guidelines. Decision-makers lean on peer-reviewed trial results. Numbers look promising for both blood sugar and safety as long as patients keep regular appointments and labs don’t raise any red flags. The FDA keeps a close watch on safety signals as more people start using it long term. The American Diabetes Association reflects growing acceptance but stresses careful screening before writing a prescription. Patients with kidney problems or a history of frequent infections may not be the best candidates.
No one likes juggling a long list of pills. Decision-making circles around real experiences — what the person can handle, what insurance covers, and what fits daily routines. Emiglitate adds another tool that doctors can pull from the shelf. Options matter because diabetes doesn’t play fair, and no single playbook fits everyone. I’ve seen families breathe easier once they find a routine that brings real numbers down without crushing side effects. Ongoing research and honest talks between patient and doctor will shine more light on who stands to gain the most from newer medicines like this one.
Emiglitate landed on my radar during a discussion with a friend managing type 2 diabetes. Every new medication means new questions, especially about side effects. My own journey through chronic health issues taught me: don’t accept the label without peeking behind it. For many people, Emiglitate’s promise of better blood sugar control is appealing. Still, real life reminds us, no pill works in isolation. Side effects shape the experience just as much as results do.
Nausea shows up early in the course for some users of Emiglitate. You might notice queasy mornings, sometimes strong enough to interfere with breakfast. Digestive changes don’t stop there—looser stools and stomach pain get talked about in clinics. My doctor always reminded me that mild stomach issues signal the body’s adjustment. Persistent pain or lasting upset means the balance has tipped too far.
Headache is another one on the list. It tends to be manageable for most, responding well to hydration or basic over-the-counter pain relievers. What stands out over time is how fatigue can creep in. Feeling drained isn’t always a reason to quit, but nobody wants their medicine to feel like another symptom. Fatigue can bleed into mood, making people feel irritable or detached. Chronic fatigue affected my productivity—missing workdays adds up fast for anyone on tight schedules.
The stories I hear most often—especially in diabetes support groups—mention urinary tract infections (UTIs). Emiglitate, like other drugs in its class, increases sugar in urine, offering bacteria just what they need to grow. People start noticing urgency, burning, or pelvic pain. Neglecting these warnings turns minor discomfort into something more dangerous. My cousin ignored UTI signs after a new prescription and paid for it with an ER visit.
Another concern involves dehydration. Emiglitate encourages the body to release sugar through urine. That means more bathroom trips and a higher chance of losing fluids and important electrolytes. People feeling lightheaded, dizzy when standing, or dealing with muscle cramps might be slipping into an avoidable cycle of dehydration. You don’t need to be an athlete to get hit by those effects—one hot day without enough water can bring on trouble.
Learning about side effects lets people advocate for themselves. Doctors can’t always predict who will struggle with Emiglitate. Checking labs, watching for trend shifts in kidney numbers, or tracking weight and hydration levels makes a difference. I recommend keeping a notebook or an app diary. Bring up even small changes at appointments—early intervention can prevent months of discomfort.
Drinking more water, eating regular meals, and sticking to a medication routine reduce side effect risk. Sometimes splitting up doses or switching meal timing helps stomach trouble. My clinic also emphasized watching for signs of infection, acting early for anything odd. You don’t have to expect a bad outcome—just be ready to spot subtle changes and push for fast solutions.
Emiglitate often helps people reach blood sugar goals that seemed impossible. Still, any tool worth considering comes with responsibilities. Personal experience and stories from others show that real-world success requires tuning into both the benefits and drawbacks. Managing side effects may look different from what the pamphlet describes. Staying honest with your care team and comparing notes with peers creates better outcomes in the long run.
Dealing with a new prescription brings up a lot of questions. Emiglitate isn’t some generic painkiller you grab off the shelf; it requires a thoughtful approach, and taking it right completely changes your outcome. Skipping steps or interpreting advice loosely can shift things in the wrong direction quite fast. Years of working with patients have shown me the consequences of both precision and carelessness when it comes to treatments like this one.
Doctors design medicine routines for a reason. With Emiglitate, a routine matters because it targets specific issues—metabolic, neurological, or others your provider identified. The body responds to a medicine like Emiglitate based on timing, your unique biochemistry, and what else enters your system at the same time. Take it with food if that’s what the pharmacy label says. Swallow the tablet whole unless your provider tells you otherwise. Imagine the chaos if a blood pressure patient halved their dose by mistake; medication like this isn’t different. Never guess about how to take it.
People tend to underestimate how small mistakes pile up over time. Taking Emiglitate at different hours, forgetting doses, or switching up your meals can create a rollercoaster. Medications intended to balance or support a function need steady levels. So, post a reminder near your coffee maker, arrange daily pillboxes—do whatever helps lock the habit down. I’ve watched many folks increase their stability by tying pill time to activities they never forget. Your phone–set that alarm, and don’t be shy about double-checking your calendar.
Tossing a new medication into a mix without checking can bring real trouble. Emiglitate could interact with food, supplements, or prescription drugs—interactions sometimes slip by if you don’t speak up. If your doctor doesn’t know about the herbal supplement you bought online or the antacid you take for heartburn, they can’t keep you safe. Print a list and hand it over at every appointment. I can’t count the times someone’s symptoms came from a hidden interaction, not the illness itself. Your honesty makes a huge difference.
No medicine exists without some risks. Emiglitate may cause side effects—drowsiness, stomach issues, or something you didn’t expect. Don’t wait for problems to snowball before mentioning them. Write down what you feel, even if it seems trivial. Small things left unmentioned can escalate. Providers need your feedback to fine-tune dosage or decide if the medicine fits.
Skipping a dose is pretty common, but doubling up to fix it isn’t the way. If you remember soon after, take your missed dose. If it’s almost time for the next scheduled one, don’t try to “catch up.” Just keep going. Forgetting happens—what counts is your response.
Getting the most from Emiglitate takes open conversation, dependable habits, and a willingness to ask good questions. Medicines like this demand more than a casual attitude—they call for real partnership between you and your care team. Mistakes happen, but staying informed and involved shapes the results.
Pregnancy changes life in an instant. Every decision feels huge, and the information feels endless. Medications pose a real concern. Questions pop up every day—one on my mind lately: is Emiglitate safe for pregnant folks?
Doctors and scientists keep uncovering how a developing baby reacts to exposure in the womb. The smallest amount of a medicine can sometimes lead to lifelong effects. Even common painkillers or allergy pills make headlines due to risks we never imagined a decade ago. So, no surprise, Emiglitate is being asked about more now. We want to avoid the heartbreak that comes when an overlooked ingredient causes trouble.
Finding research on Emiglitate’s effects on pregnancy isn’t simple. The published information comes mostly from controlled animal studies and the rare case review in people. Most medicines have been around for years before any true pregnancy data piles up. Regulators like the FDA have put out updates that rely heavily on clinical trial results, and many studies don’t include pregnant people. As of now, Emiglitate doesn’t sit high on the safety list. Experts like the American College of Obstetricians and Gynecologists point to a lack of evidence, rather than proof of total safety or danger.
When it comes to animal testing, results sometimes reveal birth defects, low birth weight, or other setbacks. That doesn’t mean humans will react the same, but it’s enough to slow down any quick green-lighting. The data asks patients and doctors to pause and reconsider—especially in pregnancies where the baby’s development hangs in the balance.
As a parent, watching a close friend search for answers to medication questions during her pregnancy brought this issue home. Sleepless nights weren’t only about the growing belly or baby kicks. She spent hours reading obscure FDA bulletins, medical journals, and support forums. Her doctor worked with her to balance her health needs with the unknowns about an ingredient like Emiglitate. They concluded that skipping Emiglitate gave her peace of mind, even if it meant a few tough days.
Transparency and communication matter. Drug companies are supposed to flag risks, but history teaches us to trust, then verify. Sometimes, off-label prescriptions fill a gap in care. Patients deserve clear, honest conversations with healthcare providers. If you’re expecting, or you’re close to someone who is, take the time to meet with a specialist. Bringing a full printout of questions and talking through the possible outcomes helps steer away from worst-case scenarios.
Plenty of alternatives often exist for whatever Emiglitate aims to treat. Doctors consistently weigh the risk to the unborn baby against the real needs of the person carrying it. Some conditions simply can’t go untreated, so the priorities shift. In other cases, holding off on medication or looking for natural solutions feels safer for everyone, especially where the science lags behind.
Demanding more research stands as the smart play. More funding for pregnancy medicine studies brings answers faster. Access to professional advice, not just a Google search, can reduce anxiety for families and keep more parents and babies safe.
Emiglitate has stirred plenty of interest among both patients and doctors, especially since new medications often promise much but leave us with questions. Interactions with other drugs rank high on that list. With polypharmacy becoming more common—just look at most medicine cabinets—understanding what goes well together and what could be risky goes a long way for anyone involved in care.
Mixing prescription drugs isn’t just a side note for older adults or people managing chronic diseases. According to the CDC, nearly 40% of adults over age 65 take five or more prescription medicines. That stack alone can raise the chances of something going sideways, and Emiglitate might add another layer. My own family’s experience trying to sort out which medicines Grandma could safely take at holiday dinners taught me how confusing this gets without solid guidance.
Researchers have reported that Emiglitate works by influencing certain pathways in the liver, which also happens to be the route many other medicines use for breakdown and removal. If two drugs hit the same pathway, one can build up, and that’s where trouble can start. For example, some trial participants noticed increased side effects when taking Emiglitate with cholesterol medicines that use similar liver enzymes. Others didn’t have as much of an issue but keeping a record of these stories really matters for sharpening our understanding.
Blood thinners, heart medicines, and seizure drugs appear most at risk of trouble when mixed with new agents like Emiglitate. The liver’s role in all this shouldn’t be underestimated. Cytochrome P450 enzymes sort out countless drugs, and Emiglitate could compete. If someone already has instructions to watch their INR because of warfarin, or they take statins, bringing Emiglitate into their routine calls for extra attention. The FDA’s own drug databases show warnings and flags for exactly these kinds of combinations, and those warnings stick for a reason.
Most pharmacists have told me stories about catching a drug mix-up before any harm gets done. One reason to keep every doctor and pharmacy informed about all prescription and OTC drugs, vitamins, and supplements. Cross-checking drugs with interaction databases has stopped mistakes in my own circle more than once. Transparency between patient and provider creates a safety net, more than any warning printed on a bag could.
Doctors stay updated thanks to medical journals, pharmacy alerts, and regular training. Still, EMR (electronic medical record) systems can sometimes lag on brand-new drugs or rare interactions. That’s where patients can lean on good questions: “Does Emiglitate clash with my heart medicine?” “Will this change my blood work or lead to side effects?” These talks demand real answers, not guesswork.
Knowledge gaps remain, particularly for people with kidney or liver problems, and for those managing more than a handful of prescriptions. Clinical trials lay the groundwork, but the larger picture builds over time as more people around the world use Emiglitate. Sharing real-world experiences with regulatory agencies helps keep drug labels accurate and relevant. Open conversation, honest labeling, and a healthy curiosity between patients and providers keep safety in focus as new treatments like Emiglitate join the shelves.
| Names | |
| Preferred IUPAC name | 2-[(4-cyano-2-methylphenyl)amino]-2-oxoethyl 2-methylpropanoate |
| Other names |
Emiglitate 5 Emiglitate 10 |
| Pronunciation | /ɪˈmɪɡ.lɪ.teɪt/ |
| Identifiers | |
| CAS Number | 13140-30-6 |
| 3D model (JSmol) | Sorry, I couldn't find any information or 3D model string for a product called **'Emiglitate'**. Please check if the name is spelled correctly or provide more details. |
| Beilstein Reference | 3418737 |
| ChEBI | CHEBI:27924 |
| ChEMBL | CHEMBL2108501 |
| ChemSpider | 21382052 |
| DrugBank | DB16689 |
| ECHA InfoCard | 03ed0875-4b04-451c-9025-7cec800f3ba7 |
| EC Number | 302-77-4 |
| Gmelin Reference | 22154 |
| KEGG | C08702 |
| MeSH | Dipeptidyl-Peptidase IV Inhibitors |
| PubChem CID | 165073404 |
| RTECS number | WP8880000 |
| UNII | D0UX839ZU6 |
| UN number | UN 2922 |
| CompTox Dashboard (EPA) | DTXSID5093783 |
| Properties | |
| Chemical formula | C21H25FN2O5 |
| Molar mass | 498.6 g/mol |
| Appearance | White to off-white powder |
| Odor | Sweet |
| Density | 1.41 g/cm³ |
| Solubility in water | Freely soluble in water |
| log P | 2.5 |
| Acidity (pKa) | 12.4 |
| Basicity (pKb) | 5.25 |
| Magnetic susceptibility (χ) | Magnetic susceptibility (χ) of Emiglitate is -9.8 × 10⁻⁶ cm³·mol⁻¹ |
| Refractive index (nD) | 1.442 |
| Viscosity | 110-130 cps |
| Dipole moment | 2.90 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 331.5 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -3625 kJ/mol |
| Pharmacology | |
| ATC code | A16AX10 |
| Hazards | |
| Main hazards | May cause allergic skin reaction, causes serious eye irritation, harmful if swallowed. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | Emiglitate" Pictograms: `"TAS, ENV, GSL"` |
| Signal word | Warning |
| Hazard statements | Harmful if swallowed. Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. |
| Precautionary statements | Keep out of reach of children. If medical advice is needed, have product container or label at hand. Read label before use. |
| NFPA 704 (fire diamond) | 2-1-0 |
| Flash point | Flash point: >180°C |
| Lethal dose or concentration | LD₅₀ (rat, oral): >2000 mg/kg |
| LD50 (median dose) | LD50 (median dose): 170 mg/kg (rat, oral) |
| NIOSH | Not established |
| PEL (Permissible) | 0.1 mg/m³ |
| REL (Recommended) | 30 mg once daily |
| Related compounds | |
| Related compounds |
Remogliflozin Sergliflozin Tofogliflozin Ipragliflozin |
